Nishida Haruyuki, Arikawa Yasuyoshi, Hirase Keizo, Imaeda Toshihiro, Inatomi Nobuhiro, Hori Yasunobu, Matsukawa Jun, Fujioka Yasushi, Hamada Teruki, Iida Motoo, Nishitani Mitsuyoshi, Imanishi Akio, Fukui Hideo, Itoh Fumio, Kajino Masahiro
Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Bioorg Med Chem. 2017 Jul 1;25(13):3298-3314. doi: 10.1016/j.bmc.2017.04.014. Epub 2017 Apr 13.
With the aim to find a novel long-lasting potassium-competitive acid blocker (P-CAB) that would perfectly overcome the limitations of proton pump inhibitors (PPIs), we tried various approaches based on pyrrole derivative 1b as a lead compound. As part of a comprehensive approach to identification of a new drug, we explored excellent compounds that have low lipophilicity by introducing a polar hetero-aromatic group at position 5 of the pyrrole ring. Among the compounds synthesized, fluoropyrrole derivative 37c, which has a 2-F-3-Py group at the fifth position, lower pK, and much lower ClogP and logD values than 1b dose, showed potent gastric-acid suppressive action resulting from gastric H,K-ATPase inhibition in animal models. Its maximum intragastric pH elevation effect was strong in rats, and its duration of action was much longer than that of either lansoprazole or lead compound 1b in dogs. Therefore, compound 37c can be considered a promising new P-CAB with long duration of action.